References
- Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005; 103 (6): 1103–13.
- Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Cur-rent trends in the epidemiology of nosocomial bloodstream in-fections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003; 36 (9): 1103–10.
- Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of blood-stream infections on patient outcomes in the ICU setting. Chest. 2000; 118 (1): 146–55.
- Zinner SH. New pathogens in neutropenic patients with cancer: An update for the new millennium. Int J Antimicrob Agents. 2000; 16 (2): 97–101.
- Hughes WT, Armstrong D, Bodey GP, et al. 2002 guide-lines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34 (6): 730–51.
- Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002; 34 (11): 1524–9.
- Matar MJ, Tarrand J, Raad I, Rolston Ky. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control. 2006; 34 (8): 534–6.
- Clinical and Laboratory Standards Institute. (CLSI). M100-S18, Performance standards for antimicrobial susceptibility test-ing, 18th informational supplement. Wayne, PA: CLSI. 2008.
- Clinical and Laboratory Standards Institute. (CLSI). M7-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. Wayne, PA: CLSI.; 2006.
- Ashour HM, el-Sharif A. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients. J Clin Oncol. 2007; 25 (36): 5763–9.
- Gould IM. MRSA bacteraemia. Int J Antimicrob Agents. 2007; 30 Suppl 1: S66–70.
- Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr., Eliopoulos GM. Relationship of MIC and bac-tericidal activity to efficacy of vancomycin for treatment of me-thicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42 (6): 2398–402.
- Soriano A, Marco F, Martinez JA, et al. Influence of van-comycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin In-fect Dis. 2008; 46 (2): 193–200.
- Moellering RC. Linezolid: The first oxazolidinone antimi-crobial. Ann Intern Med. 2003; 138 (2): 135–42.
- Fowler VG, Jr., Boucher HW, Corey GR, et al. Dapto-mycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006; 355 (7): 653–65.
- Pankey GA, Sabath LD. Clinical relevance of bacteriosta-tic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis. 2004; 38 (6): 864–70.
- Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro eval-uation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: A SENTRY Program Report (2003-2004). Int J Antimicrob Agents. 2007; 30 (2): 143–9.
- Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19,615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis. 2007; 57 (4): 459–65.
- Sader HS, Fritsche TR, Jones RN. Daptomycin bacterici-dal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother. 2006; 50 (7): 2330–6.
- Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Effi-cacy of daptomycin in experimental endocarditis due to methi-cillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003; 47 (5): 1714–8.
- Package Insert. Cubicin (daptomycin for injection). Lex-ington MA. (Cubist Pharmaceuticals, Inc). Available at http : //www. cubicin.com/pdf /Prescribing Information pdf . Ac-cessed on January 13, 2008.